In the last decade the inhibition of the enzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD1) emerged as a promising new strategy to treat diabetes and several metabolic syndrome phenotypes. Using a molecular modeling approach and classical bioisosteric studies, we discovered a new class of 11β-HSD1 inhibitors bearing an arylsulfonylpiperazine scaffold. Optimization of the initial lead resulted in compound 11 that selectively inhibits 11β-HSD1 (IC50=0.7 μM).
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2ivf1NM
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
A study using a new computer-aided detection (CAD) algorithm found breast cancers... Read more on AuntMinnieEurope.com Related Reading: ...
-
Predictors of postoperative pneumonia in patients undergoing oral cancer resections and its management p. 69 Ridhi Sood, Jerry Paul, Sunil...
-
This work presents the nonlinear dynamical analysis of a multilayer piezoelectric macrofiber composite (MFC) laminated shell. The effects of...
-
: local control, functional, and esthetic outcomes p. 82 Deepak Balasubramanian, Narayana Subramaniam, Sherry Peter, Latha Rao, Pramod Sub...
-
https://tophealthjournal.com/5901/why-are-there-unusual-white-spots-on-your-tongue/ A tongue is often called "the strongest muscle of...
-
Background. Peritoneal Carcinomatosis Index (PCI) is a widely established scoring system that describes disease burden in isolated colorecta...
-
This study analyzes 24 climate extreme indices over North Thailand using observed data for daily maximum and minimum temperatures and total ...
-
Abstract Background Metastatic pulmonary calcification (MPC) is rarely reported in primary hyperparathyroidism, especially MPC develops ...
-
<span class="paragraphSection">Much public health research seeks to identify harm and then use that knowledge as the basis f...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου